1. Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.
- Author
-
Alenda, Raquel, Costa-Frossard, Lucienne, Alvarez-Lafuente, Roberto, Espejo, Carmen, Rodríguez-Martín, Eulalia, de la Maza, Susana Sainz, Villarrubia, Noelia, Río, Jordi, Domínguez-Mozo, María I., Montalban, Xavier, Álvarez-Cermeño, José C., and Villar, Luisa M.
- Subjects
- *
MULTIPLE sclerosis treatment , *THERAPEUTIC use of interferons , *DISEASE relapse , *DISEASE remission , *ENZYME-linked immunosorbent assay , *FLOW cytometry - Abstract
Response to interferon-beta (IFN-beta) treatment is heterogeneous in multiple sclerosis (MS). We aimed to search for biomarkers predicting no evidence of disease activity (NEDA) status upon IFN-beta treatment in MS. 119 patients with relapsing-remitting MS (RRMS) initiating IFN-beta treatment were included in the study, and followed prospectively for 2 years. Neutralizing antibodies (NAb) were explored in serum samples obtained after 6 and 12 months of IFN-beta treatment. Soluble cytokines and blood lymphocytes were studied in basal samples by ELISA and flow cytometry, respectively. 9% of patients developed NAb. These antibodies were more frequent in patients receiving IFN-beta 1b than in those treated subcutaneous ( p = 0.008) or intramuscular ( p < 0.0001) IFN-beta 1a. No patient showing NAb remained NEDA during follow-up. Basal immunological variables are also associated with patient response. Percentages below 3% of CD19 + CD5 + cells (AUC 0.74, CI 0.63-0.84; OR 10.68, CI 3.55-32.15, p < 0.0001; Likelihood ratio 4.28) or above 2.6% of CD8 + perforin + T cells (AUC 0.79, CI 0.63-0.96; OR 6.11, CI 2.0-18.6, p = 0.0009; Likelihood ratio 5.47) increased the probability of achieving NEDA status during treatment. Basal blood immune cell subsets contribute to identify MS patients with a high probability of showing an optimal response to IFN-beta. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF